Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
166 hedge funds and large institutions have $574M invested in Eagle Pharmaceuticals, Inc. in 2020 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 50 increasing their positions, 70 reducing their positions, and 22 closing their positions.
6% more capital invested
Capital invested by funds: $540M → $574M (+$33.3M)
3% less funds holding
Funds holding: 171 → 166 (-5)
23% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 22
29% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 70
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$7.25M |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$5.12M |
| 3 |
Two Sigma Advisers
New York
|
+$3.13M |
| 4 |
Two Sigma Investments
New York
|
+$2.5M |
| 5 |
SG Americas Securities
New York
|
+$1.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$14.4M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$5.18M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.16M |
| 4 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$4.15M |
| 5 |
Renaissance Technologies
New York
|
-$2.75M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HW
176
Hancock Whitney
Gulfport,
Mississippi
| – | -$234K | -5,515 | Closed |
|
|
CGH
177
Crossmark Global Holdings
Houston,
Texas
| – | -$231K | -5,428 | Closed |
|
|
SO
178
STRS Ohio
Columbus,
Ohio
| – | -$67K | -1,600 | Closed |
|
179
Simplex Trading
Chicago,
Illinois
| – | -$59K | -1,410 | Closed |
|
|
NFG
180
Next Financial Group
Houston,
Texas
| – | -$15K | -358 | Closed |
|
|
GT
181
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$10K | -258 | Closed |
|
|
QT
182
Quantbot Technologies
New York
| – | -$9K | -225 | Closed |
|
|
CFD
183
Creative Financial Designs
Kokomo,
Indiana
| – | -$7K | -165 | Closed |
|
|
ASN
184
Advisory Services Network
Atlanta,
Georgia
| – | -$374 | -8 | Closed |
|
|
FPS
185
Fieldpoint Private Securities
Greenwich,
Connecticut
| – | +$234 | +5 | New |
|
186
Rockefeller Capital Management
New York
| – | +$889 | +19 | New |
|
EGRX Hedge Fund Activity: Q4 2020 in Review
166 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2020, worth a combined $574M — up 6.2% from $540M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of EGRX and 17 opened new positions — a net loss of 5 holders — while 70 trimmed existing stakes and 50 added.
The largest buyer was Park West Asset Management, adding an estimated $7.25M. The largest seller was Armistice Capital, cutting an estimated $14.4M.
- 166 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2020, down from 171 in Q3 2020.
- Funds reported $574M of Eagle Pharmaceuticals, Inc. stock for Q4 2020, up 6.2% quarter-over-quarter.
- 17 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2020 and 22 closed out, a net change of -5 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2020 was Park West Asset Management, an estimated $7.25M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q4 2020 was Armistice Capital, an estimated $14.4M sold.
Based on aggregated 13F filings for Q4 2020.